Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.

Total Revenue Chart for Amneal Pharmaceuticals, Inc. Class A Common Stock

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) revenue for FY2025 was USD 3.0B, a 8.0% change from FY2024. Amneal Pharmaceuticals, Inc. Class A Common Stock's revenue grew from USD 785.6M in 2014 to USD 3.0B in 2025 (284.3% over 11 years). Earnings per share grew from USD 0.94 in 2014 to USD -0.86 in 2022 (-192.0%). Revenue compound annual growth rate: 5-year CAGR of 8.7%, 10-year CAGR of 13.3%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.